Patents Represented by Attorney Robins & Pasternak LLP
  • Patent number: 8192975
    Abstract: Stable pharmaceutical compositions comprising recombinant adeno-associated virus (AAV) virions are described. The compositions provide protection against loss of recombinant AAV vector genomes and transduceability under conditions such as exposure to cycles of freezing and thawing and storage in glass or polypropylene vials. The compositions comprise recombinant AAV virions in combination with one or more dihydric or polyhydric alcohols, and, optionally, a detergent, such as a sorbitan ester. Also described are methods of using the compositions.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: June 5, 2012
    Assignee: Genzyme Corporation
    Inventors: Hema S. Sista, Yero J. Espinoza
  • Patent number: 8178128
    Abstract: A nanoparticle capable of delivery of an encapsulated molecule into a living cell. The nanoparticle includes an encapsulation media and an isolated nucleic acid homolog sequence. The encapsulation media is primarily polymeric. The nanoparticles release the encapsulated molecule over an extended period of time. Further disclosed are pharmaceutical compositions and articles of manufacture including nanoparticles and methods of preparing and using the nanoparticles.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: May 15, 2012
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Gershon Golomb, Haigt Sacks, Yousef Najareh, Elia Fishbein, Michael Chorny
  • Patent number: 8153399
    Abstract: Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: April 10, 2012
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Pei-Qi Liu, Jeffrey C. Miller
  • Patent number: 8137948
    Abstract: Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: March 20, 2012
    Assignee: Genzyme Corporation
    Inventors: Guang Qu, John Fraser Wright
  • Patent number: 8124098
    Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: February 28, 2012
    Assignee: Novartis Vaccines and Diagnostics SRL
    Inventors: Vega Masignani, Beatrice Maria Arico
  • Patent number: 8110379
    Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: February 7, 2012
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Russell DeKelver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
  • Patent number: 8101406
    Abstract: Anti-?-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to ?-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for (?-1,6-glucan.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: January 24, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Antonio Cassone, Antonella Torosantucci
  • Patent number: 8071370
    Abstract: Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: December 6, 2011
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Alan P. Wolffe, Elizabeth J. Wolffe, legal representative, Trevor Collingwood, Philip D. Gregory, Andrew Snowden, Fyodor Urnov
  • Patent number: 8062662
    Abstract: A liposome composition having a compound entrapped in a supersaturated solution and method for preparing such a composition are described.
    Type: Grant
    Filed: March 16, 2006
    Date of Patent: November 22, 2011
    Assignees: Alza Corporation, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Danilo D. Lasic, Robert M. Abra, Yechezkel Barenholz, Tal Peleg-Shulman
  • Patent number: 8034598
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: October 11, 2011
    Assignee: Sangamo Biosciences, Inc.
    Inventor: Jeffrey C. Miller
  • Patent number: 8012465
    Abstract: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced toxicity and adverse side effects compared to high dose IL-2 therapy.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: September 6, 2011
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Laurence Elias, Gary Witherell
  • Patent number: 8012946
    Abstract: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: September 6, 2011
    Assignee: Sangamo Biosciences, Inc.
    Inventors: H. Steve Zhang, Philip D. Gregory, Edward J. Rebar
  • Patent number: 8007780
    Abstract: Methods of making and using recombinant AAV vectors and virions for gene delivery to the lung are described. The recombinant AAV virions are derived from caprine AAV and bovine AAV, both of which display tropism for lung tissue.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: August 30, 2011
    Assignee: Genzyme Corporation
    Inventors: Alejandra E. Arbetman, Michael A. Lochrie
  • Patent number: 8008060
    Abstract: Two different strains of Cordyceps sinensis are placed at two different locations in a medium containing purified rattle snake venom and the two strains are allowed to grow until they meet in a boundary zone where a hybrid strain is formed due to exchange of genetic material. The hybrid strain is allowed to grow and is harvested and can be analyzed for the presence and quantity of desired medicinal substances. The amount of N6-(2-hydroxyethyl)-adenosine in a Cordyceps sinensis strain or product sample is a reliable indicator of the overall health benefiting qualities of the strain or sample. Strains of Cordyceps sinensis, are grown in a substrate at 20 to 22° C. at sea level atmospheric pressure for 28 to 30 days in diffuse light, and thereafter in an atmosphere containing approximately 50% of oxygen of the sea level atmosphere, at approximately 3° C.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: August 30, 2011
    Assignee: Aloha Medicinals Inc.
    Inventors: Phillip D. Cleaver, John C. Holliday, Megan Loomis Powers
  • Patent number: 7985417
    Abstract: A method of inserting a lipid-linked moiety into a lipid assembly, such as a planar lipid monolayer or bilayer, a spherical lipid vesicle, a micelle, or an emulsion envelope monolayer is described. In the method, the lipid assembly and the lipid-linked moiety are contacted in the presence of microwave irradiation to permit the lipid-linked moiety to become associated with the lipid assembly. In one embodiment, the lipid assembly is a liposome and the lipid-linked moiety is a lipid-polymer. Compositions comprised of a lipid layer and of a lipid-linked moiety, prepared in accord with the method, are also described.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: July 26, 2011
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yechezkel Barenholz, Olga Garbuzenko
  • Patent number: 7985887
    Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: July 26, 2011
    Assignee: Sangamo BioSciences, Inc.
    Inventors: George Norbert Cox, III, Casey Christopher Case, Stephen P. Eisenberg, Eric Edward Jarvis, Sharon Kaye Spratt
  • Patent number: 7951925
    Abstract: Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: May 31, 2011
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Dale Ando, Michael C. Holmes, Gary Ka Leong Lee
  • Patent number: 7947309
    Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: May 24, 2011
    Assignee: Fidia Farmaceutici S.p.A
    Inventors: Derek O'Hagan, Alessandra Pavesio
  • Patent number: 7947873
    Abstract: Disclosed herein are zinc finger proteins that bind to target sites in a plant gamma-tocopherol methyl transferase (GMT) gene; compositions comprising these GMT-targeted zinc finger proteins and methods of making and using such zinc finger proteins. Also disclosed are methods for modulating the alpha-tocopherol content in various plant organs, particularly seeds, in transgenic plants.
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: May 24, 2011
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Guofu Li, Qiang Liu, Andrew Jamieson, Edward Rebar, Mylavarapu Venkatramesh
  • Patent number: 7947469
    Abstract: Disclosed herein are methods and compositions for modulating HIV infection by regulating expression of one or more receptors.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: May 24, 2011
    Assignee: Gendaq, Ltd.
    Inventors: Michael Moore, Mark Isalan, Lindsey Reynolds, Christopher Ullman, John Girdlestone, Christophe Demaison, Yen Choo